2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：北京利德曼生化股份有限公司 单位：人民币元 | | | 占用方与上 | 上市公司核 | | 年半年度 2023 | 年半年 2023 | 2023 年半年度 | 2023 年半年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | 资金占用方名 | 市公司的关 | 算的会计科 | 年期初占 2023 | 占用累计发生 | 度占用资金 | 偿还累计发生 | 期末占用资金余 | 占用形成 | 占用性质 | | 用 | 称 | | | 用资金余额 | 金额（不含利 | 的利息（如 | | | 原因 | | | | | 联关系 | 目 | | | | 金额 | 额 | | | | | | | | | 息） | 有） | | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | ...

证券代码：300289 证券简称：利德曼 公告编号：2023-045 北京利德曼生化股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司(以下简称"公司")第五届董事会第 十二次会议(以下简称"本次会议")于 2023 年 8 月 11 日在北京市北京 经济技术开发区兴海路 5 号公司二层会议室以通讯方式召开。本次会 议通知于 2023 年 8 月 1 日以电子邮件方式送达全体董事，与会的各 位董事已知悉与所审议事项相关的必要信息。本次会议由董事长王凯 翔先生主持，应出席本次会议的董事 7 名，亲自出席会议的董事 7 名。 公司监事和高级管理人员列席了本次会议。本次会议的召集和召开符 合《公司法》和《公司章程》的有关规定，会议所形成的有关决议合 法、有效。经全体董事认真审议，表决通过以下议案： 一、审议通过《关于 2023 年半年度报告全文及摘要的议案》 董事会认为公司已严格按照相关法律、法规及中国证监会和深圳 证券交易所的规定，编制公司《2023 年半年度报告》及《2023 年半 年度报告 ...

证券代码：300289 证券简称：利德曼 公告编号：2023-046 北京利德曼生化股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）第五届监事会 第十次会议（以下简称"本次会议"）通知于 2023 年 8 月 1 日以电子 邮件方式向全体监事发出，与会的各位监事已知悉与所审议事项相关 的必要信息。本次会议于 2023 年 8 月 11 日在北京市北京经济技术开 发区兴海路 5 号公司二层会议室以通讯方式召开。出席会议的监事应 到 3 名，亲自出席监事 3 名，本次会议由公司监事会主席林冠宇先生 主持。本次会议的召开符合《中华人民共和国公司法》及《公司章程》 等法律、法规和内部制度的规定。会议以投票表决方式审议通过以下 议案： 一、审议通过《关于 2023 年半年度报告全文及摘要的议案》 公司监事会对《2023 年半年度报告》及《2023 年半年度报告摘 要》进行了审核，提出如下审核意见： 1、公司董事会编制和审核公司 2023 年半年度报告的程序符合法 律、行政法规、中 ...

2023 年半年度募集资金存放与实际使用情况 证券代码：300289 证券简称：利德曼 公告编号：2023-049 北京利德曼生化股份有限公司 的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号—上市公 司募集资金管理和使用的监管要求》（证监会公告〔2022〕15 号）、《深 圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》（深证上〔2022〕14 号）及相关格式指引的规定，北京利德曼生化 股份有限公司（以下简称"公司"）现将 2023 年半年度募集资金存放与 实际使用情况报告如下： 一、募集资金基本情况 (一)实际募集资金金额、资金到账情况 经中国证券监督管理委员会《关于同意北京利德曼生化股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2021〕519 号）同意 注册，公司向特定对象发行 126,213,152 股人民币普通股股票，发行价 格为 4.41 元/股，募集资金总额为人民币 556,600,000.32 元，扣除各项 发行费用（不含增值税）5,768,77 ...

中信建投证券股份有限公司 关于北京利德曼生化股份有限公司 2023 年半年度跟踪报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：利德曼 | | --- | --- | | 保荐代表人姓名：吴嘉煦 | 联系电话：010-65608214 | | 保荐代表人姓名：蔡诗文 | 联系电话：010-85130823 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 防止关联方占用公司资源的制度、募集资金管理制度、 | 是 | | 内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 2 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导情况 | | | （1） ...

Financial Performance - Revenue for Q1 2023 was CNY 108,150,382.74, a decrease of 43.55% compared to CNY 191,578,138.79 in the same period last year[5] - Net profit attributable to shareholders was CNY 8,296,310.96, down 31.49% from CNY 12,109,083.40 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.0153, a decrease of 30.45% from CNY 0.022 in the same period last year[5] - The total comprehensive income for Q1 2023 was CNY 10,109,371.69, compared to CNY 18,442,533.26 in Q1 2022, reflecting a decrease of approximately 45.0%[28] - Net profit for Q1 2023 was CNY 10,109,371.69, a decline of 45.0% compared to CNY 18,442,533.26 in Q1 2022[27] Cash Flow - Net cash flow from operating activities increased by 535.02% to CNY 27,508,461.89, compared to CNY 4,331,880.00 in the previous year[5] - Cash inflows from operating activities totaled CNY 142,616,871.69, a decrease from CNY 248,793,538.36 in the previous year, reflecting a decline of about 42.6%[30] - Cash outflows from operating activities were CNY 115,108,409.80, down from CNY 244,461,658.36, resulting in a net cash flow from operating activities of CNY 27,508,461.89, compared to CNY 4,331,880.00 in the previous year[31] - The net cash flow from investing activities improved by 87.03%, amounting to CNY -41,878,200.00, compared to CNY -322,868,300.00 in the same period last year[14] - The net cash flow from financing activities was CNY -2,782,067.94, an improvement from CNY -4,452,419.68 in the previous year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,941,239,161.02, a decrease of 2.80% from CNY 1,997,134,641.92 at the end of the previous year[5] - Total liabilities decreased to CNY 150,662,386.21 in Q1 2023 from CNY 216,667,238.80 in the same period last year[25] - Cash and cash equivalents at the end of the reporting period were RMB 781.66 million, down from RMB 798.81 million at the beginning of the year[23] - The company reported a decrease in accounts receivable to CNY 165,515,052.40 from CNY 184,081,260.63 year-over-year, indicating improved collection efforts[25] Business Segments - The in vitro diagnostic reagent business generated RMB 89.06 million in revenue, a decline of 46.15%, accounting for 82.34% of total revenue[18] - The diagnostic instruments (including accessories and consumables) segment reported revenue of RMB 4.83 million, down 61.96%, representing 4.47% of total revenue[18] Research and Development - Research and development expenses for Q1 2023 amounted to CNY 8,464,282.68, a decrease of 7.3% from CNY 9,130,522.32 in Q1 2022[27] - The company has four new products under registration and one new biochemical diagnostic reagent product has obtained registration certification[18] - The company added one new utility model patent and one new invention patent application during the reporting period[19] Shareholder Activities - The company completed a share buyback plan, with Vice President Ding Yaoliang purchasing 1,140,000 shares for a total of RMB 6.99 million[20] - The company paid a total of RMB 39.35 million as the remaining transfer price for acquiring a 51% stake in Guotuo (Xiamen) Cold Chain Logistics Co., Ltd.[21] Other Information - The company reported a 100% decrease in accounts payable, dropping to CNY 0.00 from CNY 1,967,200.00 due to the payment of matured acceptance bills[10] - The company's weighted average return on equity decreased to 0.48% from 0.66% year-on-year[5] - The company's total equity attributable to shareholders increased by 0.48% to CNY 1,735,601,004.17 from CNY 1,727,304,693.21 at the end of the previous year[5] - The Q1 2023 report was not audited, indicating that the figures are preliminary and subject to change[32]

Group 1: Financial Performance - In 2022, the company achieved a total revenue of 705.98 million CNY, with a net profit attributable to shareholders of -56.27 million CNY [8] - The revenue from in vitro diagnostic reagents accounted for 87.79% of total revenue, amounting to 619.81 million CNY [4] - The company reported a decrease in cash of 12.98 million CNY, a decline of 13.98% from the previous year, primarily due to payments for acquisitions [5] Group 2: Research and Development - The R&D investment in 2022 was 34.96 million CNY, representing a growth of 6.37% compared to the previous year [4][5] - The company focuses on developing products in three main areas: external diagnostic reagents, diagnostic instruments, and biochemical raw materials [2] - The company aims to enhance its R&D capabilities by adopting collaborative and commissioned R&D approaches [3] Group 3: Market Position and Strategy - The company holds a leading position in the biochemical diagnostic reagent market, recognized for its diverse product offerings and stable quality [5] - The company plans to expand into molecular diagnostics and POCT (Point of Care Testing) while maintaining its core business in biochemical diagnostics [4] - The company’s strategic goal is to become a comprehensive, technology-driven, and marketing-leading enterprise in the in vitro diagnostic industry [8] Group 4: Regional Revenue Distribution - In 2022, revenue distribution was as follows: East China accounted for 66.25%, North China 14.57%, South China 7.09%, and the remaining regions (Central, Northwest, Southwest, Northeast) collectively contributed 12.08% [3] Group 5: Challenges and Future Plans - The company faces challenges in maintaining profitability, with significant expenses in sales, management, and R&D [8] - Future plans include optimizing the existing production system, enhancing operational efficiency, and establishing a talent system to support growth [3][8] - The company is exploring various financing channels to support operational needs and potential acquisitions [6]

证券代码：300289 证券简称：利德曼 公告编号：2023-026 北京利德曼生化股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更深入全面地了解公司经营情况，公司定于 2023 年 4 月 11 日（星期二）下午 15:00 至 17:00 时举行 2022 年度业 绩说明会。本次年度业绩说明会将采取网络远程方式举行，投资者可 通过以下方式参与本次互动交流： 参与方式一：在微信中搜索"利德曼投资者关系小程序"； 参与方式二：微信扫描以下二维码： 投资者依据提示，授权登入"利德曼投资者关系"小程序，即可 参与交流。 为提升交流效率和针对性，以及做好中小投资者保护工作，广泛 听取投资者的意见和建议，增进投资者对公司的了解和认同，提升公 司治理水平和企业整体价值，现提前向投资者征集相 ...

Financial Performance - The company achieved operating revenue of 705.9768 million yuan, an increase of 25.16% compared to the same period last year[4]. - The net profit attributable to shareholders was -56.2718 million yuan, a decrease of 351.00% year-on-year, primarily due to goodwill impairment of 30.5286 million yuan and credit impairment of 27.5273 million yuan[4]. - The company's operating revenue for 2022 was ¥705,976,839.21, representing a 25.16% increase compared to ¥564,057,983.88 in 2021[27]. - The net profit attributable to shareholders for 2022 was -¥56,271,757.90, a decrease of 351.00% from a profit of ¥22,419,197.58 in 2021[27]. - The net cash flow from operating activities was ¥108,933,825.70, a decline of 8.50% from ¥119,058,284.44 in 2021[27]. - The total assets at the end of 2022 were ¥1,997,134,641.92, a decrease of 14.96% from ¥2,348,410,268.66 at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were ¥1,727,304,693.21, down 5.87% from ¥1,835,030,234.33 in 2021[27]. - The basic earnings per share for 2022 was -¥0.10, compared to ¥0.05 in 2021, reflecting a 300.00% decrease[27]. - The weighted average return on net assets was -3.13% in 2022, a decline of 4.66% from 1.53% in 2021[27]. - The company reported uncertainty regarding its ability to continue as a going concern, as both net profits before and after deducting non-recurring gains and losses have been negative for the last three accounting years[27]. Revenue Sources - Revenue from epidemic prevention testing business was 254.20 million yuan, with future revenue expected to focus on biochemical and immunodiagnostic products[4]. - The in vitro diagnostic reagent business generated revenue of 619.81 million yuan, up 28.43% year-on-year, accounting for 87.79% of total revenue[57]. - Revenue from the biopharmaceutical sector was ¥675,935,938.66, accounting for 95.74% of total revenue, with a growth of 24.96% year-on-year[84]. - The East China region contributed ¥467,722,330.17, which is 66.25% of total revenue, showing a significant growth of 62.27% year-on-year[84]. - The distribution sales model accounted for ¥566,472,687.71, or 80.24% of total revenue, with a year-on-year increase of 30.35%[84]. Research and Development - The company emphasizes continuous investment in R&D, upgrading existing products, and expanding product lines to meet end-user testing needs[57]. - The company has established multiple product development and technology innovation platforms, including biochemical and immunodiagnostic reagent development platforms[61]. - The company is actively investing in research and development for high-tech immunodiagnostic products, which are characterized by high technological content and long development cycles[41]. - The company has a R&D team of 73 people, with 29 holding master's degrees or higher, contributing to its core competitiveness in technology development[63]. - The company reported a research and development expenditure of ¥34,957,360.92 in 2022, which represents 4.95% of its operating revenue[98]. - The company has registered and launched multiple new test kits, including those for rT3, DHEAS, and S100, enhancing its testing menu in various categories[97]. - The company aims to enhance its biochemical detection capabilities and expand its testing menu for conditions such as hypertension and anemia[96]. Market and Competition - The company operates in the in vitro diagnostics (IVD) industry, which is projected to reach USD 59.45 billion in sales by 2024, with a compound annual growth rate (CAGR) of 6.1% from 2017 to 2024[38]. - The domestic IVD market size was estimated at approximately CNY 146 billion in 2022, with a six-year CAGR of about 21%, highlighting rapid growth in the sector[39]. - Increased market competition in the in vitro diagnostics industry may affect the company's operational performance if it cannot maintain its core competitiveness[7]. - The domestic biochemical diagnostic field has a current domestic substitution rate of approximately 70%, indicating significant market potential for domestic products[62]. - The company is focusing on collaboration with universities and research institutions to drive innovation and product development[63]. Governance and Compliance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholder interests and sustainable development[146]. - The company maintains transparency in information disclosure, ensuring all shareholders have equal access to information[153]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to performance[151]. - The company has not experienced any significant deviations from the governance regulations set by the China Securities Regulatory Commission[154]. - The company is committed to ensuring the accuracy of its financial reporting and compliance with regulations[122]. Strategic Initiatives - The company plans to improve profitability through product system layout, accelerate new product launches, and optimize supply chain management[4]. - The company is focusing on expanding its product line in molecular diagnostics and point-of-care testing (POCT) to meet diverse market demands[40]. - The company is actively adjusting its marketing strategies through various channels to enhance brand recognition and academic influence[58]. - The company plans to continue its strategic initiatives in market expansion and product development[117]. - The company aims to improve its market position through continuous innovation and product development[100]. Risks and Challenges - The company faces risks from industry policy changes, including centralized procurement and price control measures that may impact profitability[5]. - The company is at risk of asset impairment due to potential uncollectible receivables from downstream customers affected by economic conditions[10]. - The company reported a significant increase in external purchase costs, which rose by 127.58% year-on-year to ¥268,966,074.25[88]. - The company is committed to enhancing its governance structure and internal control systems to reduce operational compliance risks and improve information disclosure quality[141].

Financial Performance - The company's revenue for Q3 2022 was ¥167,677,605.14, a decrease of 0.66% compared to the same period last year, while year-to-date revenue increased by 30.81% to ¥541,955,931.31[4] - Net profit attributable to shareholders for Q3 2022 was ¥10,533,956.80, down 32.01% year-on-year, with year-to-date net profit increasing by 18.62% to ¥34,469,678.83[4] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥8,682,676.22, a decrease of 43.57% year-on-year, while year-to-date it increased by 10.97% to ¥29,757,670.58[4] - Total operating revenue for the third quarter reached ¥541,955,931.31, an increase of 30.8% compared to ¥414,305,890.57 in the same period last year[23] - Net profit for the period was ¥49,863,077.17, slightly down from ¥50,012,250.46 in the previous year, representing a decrease of 0.3%[24] - The net profit attributable to shareholders of the parent company was ¥34,469,678.83, an increase of 18.3% compared to ¥29,057,757.37 in the same period last year[24] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥78,295,528.10, an increase of 58.81% compared to the previous year[4] - The cash inflow from operating activities for Q3 2022 was CNY 667,753,861.95, an increase of 26.9% compared to CNY 525,904,241.09 in Q3 2021[27] - The cash flow from operating activities netted CNY 78,295,528.10, which is a 58.8% increase compared to CNY 49,300,438.01 in Q3 2021[27] - The cash received from other operating activities was CNY 11,647,624.61, compared to CNY 9,669,930.04, marking a 20.5% increase[27] Operating Costs - Operating costs increased by 56.40% year-to-date, mainly due to the purchase of COVID-19 testing reagents[9] - Total operating costs amounted to ¥478,638,335.45, up 36.3% from ¥350,959,659.12 year-on-year[23] - The cash paid for purchasing goods and services was CNY 374,893,475.53, up from CNY 274,669,214.59, indicating a 36.4% increase in operational costs[27] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,338,864,516.45, a decrease of 0.41% from the end of the previous year[4] - Total liabilities amounted to ¥322,499,967.10, a decrease from ¥370,301,842.38 at the end of the previous period[23] - The company has a total asset value of 2,338,864,516.45 CNY as of September 30, 2022, down from 2,348,410,268.66 CNY at the beginning of the year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,378[13] - The largest shareholder, Guangzhou High-tech Zone Technology Holding Group Co., Ltd., holds 46.35% of shares, totaling 252,133,152 shares[13] Research and Development - Research and development expenses for the quarter were ¥28,351,916.96, up from ¥24,493,747.55 year-on-year, indicating a focus on innovation[23] - The company has added 8 new patent authorizations during the reporting period, including a method for detecting invasive fungal infections[17] Investment Activities - The net cash outflow from investing activities was CNY -327,437,026.83, compared to CNY -25,002,514.27 in the same period last year, indicating a significant increase in investment expenditures[27] - The company reported a significant increase in cash outflows for investment activities, totaling CNY 660,432,992.86, compared to CNY 59,171,716.40 in the previous year[27] Goodwill and Other Assets - The company has a total of 190,072,267.77 CNY in goodwill, unchanged from the beginning of the year[20] - The company has a total of 149,905,196.83 CNY in investment properties as of September 30, 2022[20]